A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.

Conditions

Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
AD

Interventions

DRUG: Placebo
DRUG: IMG-007

Sponsor

Inmagene LLC